{"filing":{"accession_number":"0001213900-26-098976","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-09-11","report_date":"2026-09-11","primary_document":"ea0305226-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026098976/ea0305226-6k_radiopharm.htm"},"events":[{"id":32818,"run_id":30170,"accession_number":"0001213900-26-098976","anchor_item_number":"EX-99.1","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This exhibit discloses the results of an Extraordinary General Meeting held on 11 September 2026, with detailed proxy vote tallies and poll outcomes for eight resolutions. The resolutions cover material capital-raising activities including ratification and approval of placement share issuances, options, and warrants, as well as director and CEO equity grants. All resolutions were carried. This is a classic shareholder_vote_results disclosure under the ASX Listing Rule 3.13.2 and Corporations Act Section 251AA(1), and the equity issuances and director compensation approvals are material to investors.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-09-11","form":"6-K","submitted_at":null,"items":[{"id":36084,"accession_number":"0001213900-26-098976","item_number":"EX-99.1","item_title":"ea030522601ex99-1.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This exhibit discloses the results of an Extraordinary General Meeting held on 11 September 2026, with detailed proxy vote tallies and poll outcomes for eight resolutions. The resolutions cover material capital-raising activities including ratification and approval of placement share issuances, options, and warrants, as well as director and CEO equity grants. All resolutions were carried. This is a classic shareholder_vote_results disclosure under the ASX Listing Rule 3.13.2 and Corporations Act Section 251AA(1), and the equity issuances and director compensation approvals are material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T12:01:52.709761+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36084,"accession_number":"0001213900-26-098976","item_number":"EX-99.1","item_title":"ea030522601ex99-1.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This exhibit discloses the results of an Extraordinary General Meeting held on 11 September 2026, with detailed proxy vote tallies and poll outcomes for eight resolutions. The resolutions cover material capital-raising activities including ratification and approval of placement share issuances, options, and warrants, as well as director and CEO equity grants. All resolutions were carried. This is a classic shareholder_vote_results disclosure under the ASX Listing Rule 3.13.2 and Corporations Act Section 251AA(1), and the equity issuances and director compensation approvals are material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T12:01:52.709761+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-09-11"}]}